Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ALMS
stocks logo

ALMS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent
Wall Street analysts forecast ALMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALMS is 19.50 USD with a low forecast of 14.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast ALMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALMS is 19.50 USD with a low forecast of 14.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.300
sliders
Low
14.00
Averages
19.50
High
25.00
Current: 8.300
sliders
Low
14.00
Averages
19.50
High
25.00
Wells Fargo
Derek Archila
Overweight
initiated
$17
2025-07-25
Reason
Wells Fargo
Derek Archila
Price Target
$17
2025-07-25
initiated
Overweight
Reason
Wells Fargo analyst Derek Archila initiated coverage of Alumis with an Overweight rating and $17 price target. The firm says the bull case on the shares centers around A-005 in multiple sclerosis and ESK-001's opportunity in systemic lupus erythematosus.
Guggenheim
Yatin Suneja
initiated
$18
2025-06-10
Reason
Guggenheim
Yatin Suneja
Price Target
$18
2025-06-10
initiated
Reason
Guggenheim analyst Yatin Suneja resumed coverage of Alumis with a Buy rating and $18 price target with the merger with Acelyrin completed. The firm, which highlights the two recent milestones of the announcement of the 52-week Phase 2 OLE data for ESK-001 in psoriasis in March and the completion of Phase 3 ONWARD trials patient enrollment, updated its model to reflect the new share count and cash position post-Acelyrin merger.
Morgan Stanley
NULL -> Overweight
initiated
$23
2025-06-01
Reason
Morgan Stanley
Price Target
$23
2025-06-01
initiated
NULL -> Overweight
Reason
Morgan Stanley resumed coverage of Alumis with an Overweight rating and $23 price target. The firm updated its model for the Acelyrin merger and Q1 earnings. The Phase 3 data from Alumis' lead pipeline program ESK-001 in psoriasis in Q1 of 2026 represents the next key catalyst for the shares, the analyst tells investors in a research note. Morgan believes the company's pipeline is on track.
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Maintains
$15 → $14
2025-04-22
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$15 → $14
2025-04-22
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$15
2025-03-26
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$15
2025-03-26
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$19 → $15
2025-03-20
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$19 → $15
2025-03-20
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Alumis Inc (ALMS.O) is -2.51, compared to its 5-year average forward P/E of -1.48. For a more detailed relative valuation and DCF analysis to assess Alumis Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.48
Current PE
-2.51
Overvalued PE
-1.13
Undervalued PE
-1.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.24
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.49
Undervalued EV/EBITDA
-2.97

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
20.64
Current PS
0.00
Overvalued PS
50.56
Undervalued PS
-9.28
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ALMS News & Events

Events Timeline

(ET)
2025-11-13
16:56:54
Alumis announces Q3 revenue of $2.07M, falling short of consensus estimate of $3.14M.
select
2025-08-13 (ET)
2025-08-13
16:23:04
Alumis reports Q2 revenue $2.67M, consensus $2.43M
select
2025-07-24 (ET)
2025-07-24
07:36:58
Alumis completes patient enrollment in global LUMUS Phase 2b trial of ESK-001
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-03NASDAQ.COM
Insider Buying Update for Wednesday, December 3: GRND, ALMS

  • Grindr Insider Purchase: George Raymond Zage III purchased 300,000 shares of GRND for $3.87M at $12.89 each, with the stock trading up about 2.4% on Wednesday.

  • Previous Grindr Investment: Prior to this purchase, Zage III bought shares worth $13.15M at $13.15 each within the last year.

  • Alumis Insider Purchase: Srinivas Akkaraju bought 173,589 shares of ALMS for $1.31M at $7.55 each, contributing to a total investment of $5.36M over the past year.

  • Alumis Stock Performance: Alumis shares are also trading up about 2% on Wednesday following the insider buying activity.

[object Object]
Preview
5.0
11-19NASDAQ.COM
Insider Buying Update for Tuesday, November 18: ALMS, LINE

  • Srinivas Akkaraju's Investment: Srinivas Akkaraju purchased 276,179 shares of Alumis (ALMS) at $5.25 each, totaling $1.45 million, and is currently up about 20% based on recent trading highs.

  • Previous Purchase by Akkaraju: Prior to this investment, Akkaraju bought shares worth $1.48 million at $4.61 each within the past year.

  • Robb A. Lemasters' Investment: Chief Financial Officer Robb A. Lemasters acquired 30,000 shares of Lineage for $1.01 million at a price of $33.74 per share.

  • Market Performance: Alumis shares are up approximately 8.6% on the day, while Lineage shares have increased by about 1.1%.

[object Object]
Preview
2.0
11-18NASDAQ.COM
NOTV and APLT Top After-Hours Biotech Gains; ALMS, TELA, CORT, and BRTX Also Show Progress

  • Biotech Gains in After-Hours Trading: Several small-cap biotech companies saw significant stock price increases in after-hours trading, driven by earnings updates and regulatory news.

  • Inotiv, Inc. Performance: Inotiv, Inc. experienced a 36.61% surge to $0.94 after announcing preliminary Q4 and full-year 2025 revenue projections, recovering from a prior decline.

  • Applied Therapeutics and Alumis Updates: Applied Therapeutics rose 16.89% following a positive earnings report, while Alumis advanced 7.09% despite a wider Q3 net loss, supported by collaboration income.

  • Regulatory Developments for BioRestorative: BioRestorative Therapies gained 8.06% after announcing a meeting with the FDA to discuss a potential accelerated pathway for its treatment of chronic lumbar disc disease.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Alumis Inc (ALMS) stock price today?

The current price of ALMS is 8.3 USD — it has increased 5.87 % in the last trading day.

arrow icon

What is Alumis Inc (ALMS)'s business?

Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.

arrow icon

What is the price predicton of ALMS Stock?

Wall Street analysts forecast ALMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALMS is 19.50 USD with a low forecast of 14.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Alumis Inc (ALMS)'s revenue for the last quarter?

Alumis Inc revenue for the last quarter amounts to 2.07M USD, decreased % YoY.

arrow icon

What is Alumis Inc (ALMS)'s earnings per share (EPS) for the last quarter?

Alumis Inc. EPS for the last quarter amounts to -1.06 USD, decreased -38.01 % YoY.

arrow icon

What changes have occurred in the market's expectations for Alumis Inc (ALMS)'s fundamentals?

The market is revising Downward the revenue expectations for Alumis Inc. (ALMS) for FY2025, with the revenue forecasts being adjusted by -1.36% over the past three months. During the same period, the stock price has changed by 84.04%.
arrow icon

How many employees does Alumis Inc (ALMS). have?

Alumis Inc (ALMS) has 168 emplpoyees as of December 05 2025.

arrow icon

What is Alumis Inc (ALMS) market cap?

Today ALMS has the market capitalization of 866.47M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free